If you have been reading about Hepatocyte growth factor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
== Overdose == As with other GABAergic drugs, combination with other drugs that depress the respiratory system, such as alcohol, sedatives, and opioids, is risky. Overdose symptoms are similar to those of other GABAergics, including excessive sedation and unresponsiveness to stimuli, severe ataxia, amnesia, confusion, agitation, intoxication, and inappropriate (potentially violent) behavior. Severe overdoses may present with respiratory depression (and subsequent pulmonary aspiration), coma, and death. Carisoprodol is not detected on all toxicology tests, which may delay diagnosis of overdose. Overdose symptoms in combination with opiates are similar but are distinguished by the presentation of normal or pinpoint pupils, which are generally unresponsive to light. Carisoprodol (as with its metabolite meprobamate) is particularly dangerous in combination with alcohol. Flumazenil (the benzodiazepine antidote) is not effective in managing carisoprodol overdose as carisoprodol acts at the barbiturate binding site. Treatment mirrors that of barbiturate overdoses and is generally supportive, including the administration of mechanical respiration and pressors as indicated and, in rare cases, bemegride. Total amnesia of the experience is not uncommon following recovery. In 2014, actress Skye McCole Bartusiak died of an overdose due to the combined effects of carisoprodol, hydrocodone, and difluoroethane. In 1999, actress Dana Plato died after taking carisoprodol with the hydrocodone/paracetamol painkiller Lortab, in an overdose that was ruled a suicide.
==== 2023 All-Ireland Senior Football Championship ==== 30 July – Dublin won their 31st All-Ireland football title after a 1–15 to 1–13 win against defending champions Kerry in the All-Ireland SFC final.
Changes in pH, surfactant concentration, and concentration of organic modifier play a significant role in determining the chromatographic separation. Often one or more of these parameters need to be optimized to achieve the desired separation, yet the optimum parameters must take all three variables into account simultaneously. The review by Garcia-Alvarez-Coque et al. mentioned several successful models for varying scenarios, a few of which will be mentioned here. The classic models by Armstrong and Nome and Foley are used to describe the general cases. Foley's model applies to many cases and has been experimentally verified for ionic, neutral, polar and nonpolar solutes; anionic, cationic, and non-ionic surfactants, and C8, C¬18, and cyano stationary phases. The model begins to deviate for highly and lowly retained solutes. Highly retained solutes may become irreversibly bound to the stationary phase, where lowly retained solutes may elute in the column void volume. Other models proposed by Arunyanart and Cline-Love and Rodgers and Khaledi describe the effect of pH on the retention of weak acids and bases. These authors derived equations relating pH and micellar concentration to retention. As the pH varies, sigmoidal behavior is observed for the retention of acidic and basic species. This model has been shown to accurately predict retention behavior. Still other models predict behavior in hybrid micellar systems using equations or modeling behavior based on controlled experimentation.
=== Early radiation consequences === The discovery of X-rays by Wilhelm Conrad Röntgen (1845-1923) in 1895 led to extensive experimentation by scientists, physicians, and inventors. The first X-ray machines produced extremely unfavorable radiation spectra for imaging with extremely high skin doses. In February 1896, John Daniel and William Lofland Dudley (1859–1914) of Vanderbilt University conducted an experiment in which Dudley's head was X-rayed, resulting in hair loss. Herbert D. Hawks, a graduate of Columbia University, suffered severe burns on his hands and chest during demonstration experiments with X-rays. Burns and hair loss were reported in scientific journals. Nikola Tesla (1856–1943) was one of the first researchers to explicitly warn of the potential dangers of X-rays in the Electrical Review on May 5, 1897 - after initially claiming them to be completely harmless. He suffered massive radiation damage after his experiments. Nevertheless, some doctors at the time still claimed that X-rays had no effect on humans. Until the 1940s, X-ray machines were operated without any protective safeguards. Röntgen himself was spared the fate of the other X-ray users by habit. He always carried the unexposed photographic plates in his pockets and found that they were exposed if he remained in the same room during the exposure. So he regularly left the room when he took X-rays.
Sources: en.wikipedia.org
=== Pharmacodynamics === Benzodiazepine like compounds are acting as positive allosteric modulators to the gamma-aminobutyric acid GABAA receptor. GABA is the main inhibitor of neurotransmitters in the brain and modulates the activity of many neurons. Benzodiazepines bind to the GABAA receptor inducing a conformational change leading to an increased affinity to GABA. The allosteric binding site is situated in a "pocket" created by the alpha and gamma subunits. The pharmacological effects on benzodiazepines vary based on which alpha subunit of the GABAA receptor the benzodiazepine binds to. The sedative, anterograde amnesic, anticonvulsant actions, and the addictive nature of benzodiazepines, are due to the binding to the α1 subunit of the (GABA)A receptor. Binding to the α2 subunit will cause the anxiolytic effects, and binding to the α2, α3, and α5 subunits will lead to the myorelaxant effects. According to research done by the WHO bromazolam binds to the α1, α2, and α5 subunits.
==== Metabolism ==== Suvorexant is metabolized primarily by hydroxylation via CYP3A enzymes. CYP2C19 also contributes to suvorexant metabolism to a minor extent. The major circulating forms are suvorexant and its metabolite hydroxysuvorexant. The hydroxysuvorexant (M9) metabolite is not expected to be pharmacologically active. It showed 10-fold lower affinity for the orexin receptors than suvorexant in vitro, was a substrate for P-glycoprotein making it unlikely to cross the blood–brain barrier, and did not show sedative effects in animal studies. Suvorexant also has several other minor metabolites.
According to Google patent search, Masliah's name appears on 28 patents, including several patents filed by Prothena Biosciences, as well as earlier patents filed in conjunction with UCSD for drugs that target synucleopathies. Research trials on the drugs cerebrolysin and minzasolmin were also found to be based on questionable data from Masliah's lab. Masliah co-authored 21 papers on the pig brain extract cerebrolysin, eight of which have been discovered to have issues. Cerebrolysin is marketed as containing "neurotrophic peptides" but researchers using high performance liquid chromatography found that it does not contain peptides, and is largely composed of amino acids and salt, with some trace protein fragments. Some of the fraudulent papers on cerebrolysin co-authored by Masliah appear to have been quite influential in boosting interest in cerebrolysin, which is used today in countries like Russia to treat stroke, dementia, and other conditions. Masliah received funding for many of his cerebrolysin studies from the maker of cerebrolysin, EVER Pharma, and collaborated with Herbert Moessler, former general manager at EVER Pharma, who incidentally has 19 of his own papers flagged for anomalies. Moessler and Masliah started a company, Neuropore, to investigate the drug minzasolmin in 2008. On December 16, 2024 UCB reported that a phase II clinical trial on minzasolmin involving 496 people showed that minzasolmin failed to demonstrate superiority over placebo in both primary and secondary endpoints. Masliah has not publicly commented on any of the findings against him.
The process required pressing tungsten powder into bars, then several steps of sintering, swaging, and then wire drawing. It was found that very pure tungsten formed filaments that sagged in use, and that a very small "doping" treatment with potassium, silicon, and aluminum oxides at the level of a few hundred parts per million (so-called AKS tungsten) greatly improved the life and durability of the tungsten filaments. The predominant mechanism for failure in tungsten filaments even now is grain boundary sliding accommodated by diffusional creep. During operation, the tungsten wire is stressed under the load of its own weight and because of the diffusion that can occur at high temperatures, grains begin to rotate and slide. This stress, because of variations in the filament, causes the filament to sag nonuniformly, which ultimately introduces further torque on the filament. It is this sagging that inevitably results in a rupture of the filament, rendering the incandescent lightbulb useless.
In cancer, there are substantial metabolic derangements that occur to ensure the proliferation of tumor cells, and consequently metabolites can accumulate which serve to facilitate tumorigenesis, dubbed oncometabolites. Among the best characterized oncometabolites is 2-hydroxyglutarate which is produced through a heterozygous gain-of-function mutation (specifically a neomorphic one) in isocitrate dehydrogenase (IDH) (which under normal circumstances catalyzes the oxidation of isocitrate to oxalosuccinate, which then spontaneously decarboxylates to alpha-ketoglutarate, as discussed above; in this case an additional reduction step occurs after the formation of alpha-ketoglutarate via NADPH to yield 2-hydroxyglutarate), and hence IDH is considered an oncogene. Under physiological conditions, 2-hydroxyglutarate is a minor product of several metabolic pathways as an error but readily converted to alpha-ketoglutarate via hydroxyglutarate dehydrogenase enzymes (L2HGDH and D2HGDH) but does not have a known physiologic role in mammalian cells; of note, in cancer, 2-hydroxyglutarate is likely a terminal metabolite as isotope labelling experiments of colorectal cancer cell lines show that its conversion back to alpha-ketoglutarate is too low to measure. In cancer, 2-hydroxyglutarate serves as a competitive inhibitor for a number of enzymes that facilitate reactions via alpha-ketoglutarate in alpha-ketoglutarate-dependent dioxygenases. This mutation results in several important changes to the metabolism of the cell.
Sources: en.wikipedia.org
For the advanced economies, there is an unmistakable need to restore fiscal sustainability through credible consolidation [deficit reduction] plans. At the same time we know that slamming on the brakes too quickly will hurt the recovery and worsen job prospects. So fiscal adjustment must resolve the conundrum of being neither too fast nor too slow. Shaping a Goldilocks fiscal consolidation is all about timing. What is needed is a dual focus on medium-term consolidation and short-term support for growth and jobs. That may sound contradictory, but the two are mutually reinforcing. Decisions on future consolidation, tackling the issues that will bring sustained fiscal improvement, create space in the near term for policies that support growth and jobs.
=== Legal status === CBN is not listed in the schedules set out by the United Nations' Single Convention on Narcotic Drugs from 1961 nor their Convention on Psychotropic Substances from 1971, so the signatory countries to these international drug control treaties are not required by these treaties to control CBN.
== Popular culture == Pan-Slavic countries, organisations, and alliances appear in various works of fiction. In the 2014 turn-based strategy 4X game Civilization: Beyond Earth there is a playable faction called the Slavic Federation – a science fiction vision of Eastern Europe and Western Asia, reformed into a powerful unified state with a focus on aerospace, technological research, and terrestrial engineering. Its leader, a former cosmonaut named Vadim Kozlov voiced by Mateusz Pawluczuk, speaks a mixture of Russian and Ukrainian with a heavy Polish accent. In the historical grand strategy games of Crusader Kings II and Europa Universalis IV, the player is able to unite Slavonic territories via political alliances and multi-ethnic kingdoms. The real-time strategy games Ancestors Legacy and the HD edition of Age of Empires II feature fictionalised versions of the early Slavs that incorporate and fuse elements from different Slavic nations.
He saw that Britain's future lay in being part of the European Economic Community, and he established ties with the European Organization for Nuclear Research (CERN), the European Molecular Biology Organization (EMBO) and the European Space Research Organization (ESRO). In 1959, the Royal Society provided for only one research fellowship, the Foulerton Professorship, but in 1961, at his suggestion, the Henry Dale Research Professorship was created for a researcher in physiology and pharmacology. Government funding was provided to create three more professorships in 1964, and another two in 1967. Reflecting his attempt to move with the times, a chair was established for the social sciences, and two new lecture series were instituted, for technology and the behavioural sciences. Aware of the acute danger of overpopulation that the life-saving drugs that he had pioneered could cause, he established a population study group, and in 1967, he became the president of the Family Planning Association.
People who receive atoltivimab/maftivimab/odesivimab should avoid the concurrent administration of a live vaccine due to the treatment's potential to inhibit replication of a live vaccine virus indicated for prevention of Ebola virus infection and possibly reduce the vaccine's efficacy. Atoltivimab/maftivimab/odesivimab is a combination of Zaire ebolavirus glycoprotein-directed human monoclonal antibodies. The three antibodies target the glycoprotein that is on the surface of the Ebola virus. This glycoprotein normally attaches to the cell via a receptor and fuses the viral and host cell membranes allowing the virus to enter the cell. The antibodies can bind to it simultaneously at three different locations and block attachment and entry of the virus. This combination drug targets the Zaire species of Ebola virus. The Sudan and Bundibugyo strains have also caused outbreaks, and it is unlikely that it would be effective against these strains.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.